Real Chemistry Introduces Real Chemistry ANATOMI, an AI Ecosystem Designed Specifically for Healthcare Commercialization

On 15 July 2026, Real Chemistry launches the ANATOMI AI solution to transform healthcare commercialization through smart marketing, medical communications, regulatory compliance, and data visions on its 25th anniversary. It focuses on accelerating innovation, boosting patient engagement, and revolutionizing lifecycle sciences strategies worldwide.

Real Chemistry launched ANATOMI on its 25th anniversary, an AI ecosystem transforming healthcare invention commercialization. ANATOMI uses AI in marketing, medical affairs, and publishing to develop strategies, create compliant content, optimize operations, and boost engagement on a single platform. By combining healthcare data, third-party sources, LLMs, and orchestration tools, it supports pharmaceutical and medicine providers throughout the product lifecycle. Using analytics, automation, and healthcare-driven AI, Real Chemistry focuses on reinforcing leadership and supporting innovative therapies. It addresses regulatory needs, therapeutic complexities, and patient-focused commercialization with secure data management.

CEO Shankar Narayanan underlined the company's people-first approach, blending AI and industry expertise to enable faster decision-making. The ecosystem provides AI tools for market analysis, healthcare advertising, and scientific publishing to achieve FDA compliance, with an improved HealthGEO for geographic intelligence. CIO Andy Johnson highlighted ANATOMI’s adaptability to technological advancement and client needs, encouraging cross-departmental collaboration. This highlights AI’s important role in healthcare, pharmaceuticals, marketing, and investment. Experts see ANATOMI as a breakthrough, replacing fragmented workflows with integrated, data-driven ecosystems.

Impact on the Life Sciences Industry

The global life science market size is valued at USD 100.88 billion in 2025. It is predicted to increase from USD 112.93 billion in 2026 to approximately USD 311.64 billion by 2035, expanding at a CAGR of 11.94% from 2025 to 2035.

According to Precedence Research, as pharma invests in AI to shorten timelines and reduce costs, ANATOMI boosts productivity and enables faster, data-driven decisions through real-time healthcare insights. Real Chemistry ANATOMI will impact the pharma and life sciences industries by accelerating drug commercialization and improving efficiency. Its secure management of regulated health data fosters trust among global pharma companies.

ANATOMI addresses these by integrating AI into workflows such as market insights, medical affairs, promotional content, and omnichannel marketing. Its publication planning streamlines scientific dissemination, reducing time to clinical and research outputs. Automated compliance checks reduce regulatory risks, while AI analytics identify market opportunities and facilitate scientific communication with healthcare professionals and patients. Overall, Healthcare AI ecosystems are anticipated to boost digital investments, improve product launches, and strengthen industry competitiveness.

Impact on Clinical Communication and Collaboration Industry

The global clinical communication and collaboration market size was exhibited at USD 2.54 billion in 2025 is predicted to increase from USD 2.84 billion in 2026 to approximately USD 7.37 billion by 2035 , growing at a CAGR of 11.24% from 2026 to 2035.

According to Precedence Research, Healthcare marketing and medical communications agencies are on the brink of change as advanced AI platforms develop. AI tools for trend analysis, communication planning, media intelligence, and scientific content can improve campaign quality and reduce costs. ANATOMI automates many of these processes, ensuring regulatory compliance and efficiency. Traditionally, healthcare marketing involved manual tasks like content creation, campaign management, regulatory reviews, media monitoring, and stakeholder engagement, which required significant time and expertise.

Agencies in the pharmaceutical, biotechnology, and medical device sectors may adopt similar AI systems to enhance productivity and offer data-driven consulting. AI-powered personalized communication can better connect with physicians, patients, payers, and institutions, leading to improved commercial results. The platform demonstrates how generative AI is evolving from content creation to full commercialization, enabling agencies to shift from repetitive tasks to strategic advisory roles. As global demand for healthcare engagement increases, specialized AI ecosystems reshape the standards of competition in healthcare marketing and medical communications.

Impact on the Digital Health Industry

The global digital health market size is calculated at USD 420.08 billion in 2025 and is predicted to increase from USD 483.07 billion in 2026 to approximately USD 1,171.24 billion by 2035, expanding at a CAGR of 10.8% from 2026 to 2035.

According to Precedence Research, there is a need for domain-specific models that handle regulatory, privacy, and workflow complexities, where ANATOMI highlights the shift toward specialized AI platforms in the healthcare sector. It demonstrates how AI vendors combine large language models, analytics, healthcare data, and automation to create ecosystems that deliver business benefits. This trend is expected to increase investments in healthcare AI startups, enterprise software, cloud infrastructure, and analytics firms in regulated environments.

Technology companies may collaborate more with healthcare firms to develop AI tools for commercialization, medical affairs, research, and guidelines. The platform also underscores the need for secure AI governance to manage sensitive health data in compliance. As companies prefer industry-specific AI over generic chatbots, competition among healthcare AI providers is shifting toward driving innovation in analytics, automation, decision support, and personalized healthcare, significantly expanding the global healthcare AI market.

Expert Opinion

According to experts, a shift from general to domain-specific AI focuses on enhancing operational efficiency and regulatory compliance, aligning with the healthcare trend toward faster, compliant product launches through automation and expert oversight. Real Chemistry ANATOMI introduces a specialized AI ecosystem for regulated healthcare industries, combining chemical data, language models, automation, and healthcare compliance tools.

healthcare-focused AI like ANATOMI can boost efficiency, reduce costs, enhance communication, and accelerate patient access to new therapies. Successful implementation requires transparent AI domination, ongoing human validation, high-quality healthcare data, and flexible regulation for AI medical content. The growing competition among AI retailers to build industry-specific ecosystems could modified healthcare processes, making healthcare a key sector for enterprise AI innovation over the next generation.